Response to the Letter to the Editor Entitled “What’s Missing in Diabetes Treatment? A Novel Agent, Finerenone?”
Abstract views: 17
/ 
PDF downloads: 18
DOI:
https://doi.org/10.5281/zenodo.18462492Abstract
Letter to Editor - No Abstract
References
Akgul A, Aylı BI. Comment on “What’s Missing In Diabetes Treatment? A Novel Agent Finerenone? Diabetic Nephropathy and Finerenone.” J Eur Int Med Prof. 2025;3(4):178–179. https://doi.org/10.5281/zenodo.17454.
Öztürk İ, Yıldırım S, Polat M. What’s Missing In Diabetes Treatment? A Novel Agent Finerenone? Diabetic Nephropathy and Finerenone. J Eur Int Med Prof. 2025;3(2):89–95. https://doi.org/10.5281/zenodo.15065667.
Heerspink HJL, Agarwal R, Amor AJ, et al. Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations. Nephrol Dial Transplant. 2025 Sep 15;gfaf183. https://doi.org/10.1093/ndt/gfaf183. [Epub ahead of print]
Tuttle K, Reynolds CL, Kornowske LM, et al. Prevalence and outcomes of chronic kidney disease in type 1 diabetes. Lancet Reg Health Am. 2025;47:101130. https://doi.org/10.1016/j.lana.2025.101130.
Heerspink HJ, Cherney DZ, Groop PH, et al. People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action. Lancet Diabetes Endocrinol. 2023;11:536–540. https://doi.org/10.1016/S2213-8587(23)00168-7.
Downloads
Published
How to Cite
License
Copyright (c) 2026 İlyas Öztürk
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All articles published in this journal are licensed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
The journal is licensed under a 